You have a lot to protect, bank more than cord blood.

Regenerative Medicine

Exploring Extraordinary Medical Possibilities

In the coming years, having more cells available through Placental and Cord Blood Banking may prove beneficial for new treatments in an emerging medical field called regenerative medicine.1,2

This new science involves repairing or replacing tissues and organs that have been damaged by congenital defects, disease, trauma, or aging, and restoring their normal functions.*,1,2

Data adapted from several sources. Full references at bottom of page.
"Around the world, [patients] are taking part in experimental trials aimed at such elusive goals as treating spinal cord injuries, curing heart attacks and saving lives.. The driving force behind this medical revolution is the stem cell.... The aim of regenerative medicine is to harness the work these cells naturally do, to treat other conditions they were not necessarily designed to heal."
- From the PBS program "Innovation, Life Inspired"
Available at: http://www.pbs.org/wnet/innovation/transcript_episode6.html

What is Regenerative Medicine?

Cord blood and placenta-derived stem cells banked with LifebankUSA are indicated for hematopoietic reconstitution (the reformation of blood cellular components) for autologous use or use in first or second degree blood relatives. Any use of cord blood and placental stem cells other than for hematopoietic reconstitution is considered investigational, including regenerative medicine* therapies.

The chance that a child will use his/her own stored stem cells during his/her lifetime for currently treated conditions is estimated at 1 in 400.† These odds may increase if there is a family history of certain blood disorders or cancers. The potential risks and benefits of stem cell transplantation vary and depend on many factors, such as the amount and quality of the stem cells collected, the HLA compatibility between recipient and donor, and the client's overall health. Talk with your health care provider. For more information, call us at 1-877-LIFEBANKUSA ( 1-877-543-3226 ).

*These uses are not consistent with current labeling, are investigational and may never become standard therapy.
† Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. Biol Blood Marrow Transplant. 2008;14(3):316-322.

References:
  1. US Department of Health and Human Services. 2020: a new vision-a future for regenerative medicine. http://www.hhs.gov/reference/newfuture.shtml. Accessed Nov 14, 2011.
  2. Harris DT. Cord blood stem cells: a review of potential neurological applications. Stem Cell Rev. 2008;4(4):269-274.
  3. Bliss T, Guzman R, Daadi M, Steinberg GK. Cell transplantation therapy for stroke. Stroke. 2007;38(suppl 2):817-826.
  4. Jazedje T, Secco M, Vieira NM, et al. Stem cells from umbilical cord blood do have myogenic potential, with and without differentiation induction in vitro. J Transl Med. 2009;7:6.
  5. Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol. 2009;147(2):177-184.
  6. Shyu MK, Yuan RH, Shih JC, et al. Kinetics and functional assay of liver repopulation after human cord blood transplantation. Dig Liver Dis. 2007;39(5);455-456.
  7. Revoltella RP, Papini S, Rosellini A, et al. Cochlear repair by transplantation of human cord blood CD133+ cells to nod-scid mice made deaf with kanamycin and noise. Cell Transplant. 2008;17(6):665-678.
  8. Harris DT, Badowski M, Ahmad N, Gaballa MA. The potential of cord blood stem cells for use in regenerative medicine. Expert Opin Biol Ther. 2007;7(9):1311-1322.
  9. Dasari VR, Spomar DG, Li L, Gujrati M, Rao JS, Dinh DH. Umbilical cord blood stem cell mediated downregulation of Fas improves functional recovery of rats after spinal cord injury. Neurochem Res. 2008;33(1):134-149.
  10. Haller MJ, Viener H-L, Wasserfall C, Brusko T, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion for type 1 diabetes. Exp Hematol. 2008;36(6):710-715.